[Objective]To explore the clinical value of N-terminal pro B type natriuretic peptide (NT-proB NP) level in elderly patients with chronic heart failure. [Methods]Electrochemiluminescence assay was used to measure the serum level of NT-proBNP in 80 elderly patients with chronic heart failure(heart failure group) and 60 healthy controls(control group). According to NYHA grading, the cardiac function of heart failure pa tients was graded. Six-minute walking test was used to evaluate the exercise tolerance. [Results] Compared with control group, serum NT-proBNP level in heart failure group increased significantly[(5052.6 ± 1860.4) pg/mL vs (220.4±99.2) pg/mL]( P ＜0.01). After therapy, serum NT-proBNP level in heart failure group was significantly lower than that before therapy(5052.6±1860.4 vs 3203±1453. 4, P ＜0.01). Serum NT proBNP level was negatively correlated with left ventricular ejection fraction(r=－0. 174, P ＜0.05) and 6 mi nute walking distance(r=－0. 187, P ＜0.05). [Conclusion] Serum NT proBNP level in elderly patients with chronic heart failure increases significantly. Measuring the NT-proBNP level can evaluate the heart function and exercise tolerance and be used as the indicator of the therapeutic efficacy.%[目的]探讨检测N端脑利钠肽前体(NT-proBNP)水平在老年慢性心力衰竭患者的临床应用价值.[方法]采用电化学发光法测定80例治疗前后老年慢性心力衰竭患者(心衰组)和60例健康对照者血清(对照组) NT-proBNP水平,心力衰竭患者心功能按NYHA心功能分级,以6分钟步行试验评价运动耐量.[结果]心衰组NT-proBNP水平较对照组明显升高[(5052.6±1860.4) pg/mL vs (220.4±99.2) pg/mL,P＜0.01];心衰组治疗后NT-proBNP水平较治疗前明显降低[(5052.6±1860.4)pg/mL vs (3203±1453.4) pg/mL,P<0.01)].NT-proBNP水平与左室射血分数(LVEF)(r=-0.174,P＜0.05)和6分钟步行距离成显著负相关(r=-0.187,P<0.05).[结论]老年慢性心力衰竭患者NT-proBNP水平明显增高,其检测水平可反映老年心力衰竭患者心功能状态、运动耐量,并可作为疗效判断指标.
展开▼
